← Back to Search


Etomidate for Stroke (SISCO Trial)

Waitlist Available
Led By Aimee Aysenne, M.D.
Research Sponsored by Life Recovery Systems
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up hospital discharge or 5-7 days post-treatment (whichever comes first) and 90 +/- 10 days post stroke
Awards & highlights

SISCO Trial Summary

This trial will test whether using a device to cool the body to 32-34°C can help improve recovery in stroke patients, compared to conventional care.

Eligible Conditions
  • Stroke
  • Brain Ischemia

SISCO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~hospital discharge or 5-7 days post-treatment (whichever comes first) and 90 +/- 10 days post-stroke
This trial's timeline: 3 weeks for screening, Varies for treatment, and hospital discharge or 5-7 days post-treatment (whichever comes first) and 90 +/- 10 days post-stroke for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in neurological outcome as indicated by NIHSS
Change in neurological status as indicated by MRS
Feasibility of cooling as indicated by percentage of patients cooled to target within 1 hour of start of cooling
+3 more
Secondary outcome measures
Quality of Life as indicated by Neuro-QOL score
Rates of procedure and device related SAEs

SISCO Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ThermoSuit Cooling InductionExperimental Treatment6 Interventions
Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
Group II: Historical ControlActive Control1 Intervention
Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnesium Sulfate
Completed Phase 4
Completed Phase 4
Completed Phase 4
Completed Phase 4

Find a Location

Who is running the clinical trial?

Geisinger ClinicOTHER
148 Previous Clinical Trials
1,886,079 Total Patients Enrolled
1 Trials studying Stroke
2,386 Patients Enrolled for Stroke
Tulane University School of MedicineOTHER
33 Previous Clinical Trials
17,470 Total Patients Enrolled
Life Recovery SystemsLead Sponsor
4 Previous Clinical Trials
57 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there openings for volunteers in this experiment?

"Clinicaltrials.gov demonstrates that this trial is recruiting patients, with the initial posting on January 25th 2017 and the latest update being July 12th 2022."

Answered by AI

What medical conditions are usually addressed with Etomidate?

"Hypomagnesemia is best treated with Etomidate, which additionally shows efficacy in the prevention of hypomagnesemia and sedation for monitored anesthesia care therapy or convulsions."

Answered by AI

In what other research has Etomidate been featured?

"Etomidate was first researched at Keck Medical Center of USC in the year 2004 and has since been examined across 841 completed trials. Presently, 120 studies are active with a large concentration based out of Danville, Louisiana."

Answered by AI

To what extent has participation been recorded for this examination?

"Affirmative. Clinicaltrials.gov reveals that sign-up for this medical study, which was posted on the 25th of January 2017, is currently open. 30 patients must be enrolled from 3 separate sites."

Answered by AI
~2 spots leftby Apr 2025